OS was the primary endpoint of the SARAH study. SIR-Spheres® Y-90 resin microspheres did not show a significant improvement in OS over sorafenib.
Despite 22% of patients in the SIRT arm not receiving SIR-Spheres Y-90 resin microspheres, the median overall survival by intention-to-treat (ITT) was 8.0 vs. 9.9 months (HR: 1.15 [95% CI: 0.94-1.41]; p=0.18) for SIRT vs sorafenib. Moreover, for patients who received SIR-Spheres Y-90 resin microspheres or sorafenib according to the SARAH protocol, median OS was 9.9 vs. 9.9 months (HR: 0.99 [95% CI: 0.79-1.24]; p=0.92).
Reprinted from The Lancet Oncology, Vol. 18, Vilgrain V, Pereira H, Assenat E et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Pages 1624-1636., Copyright (2017), with permission from Elsevier.
Vilgrain V et al. Lancet Oncol 2017; 18: 1624–36.